Publication | Open Access

Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial

VaccinologyVaccine SafetyVaccinationVaccine DevelopmentVaccine SurveillanceImmunologyVaccine TestingHumoral ImmunityVaccine EfficacyMedicineVaccine ResearchMrna Vaccine Cs-2034